-- Presentation to be webcast on www.exelixis.com -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 3, 2014-- Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the Goldman Sachs 35th Annual Global Healthcare Conference taking place next week in Rancho Palos Verdes, California. The Exelixis presentation is scheduled for 12:20 p.m. EDT/9:20 a.m. PDT on Tuesday, June 10, 2014. The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Medi...

- Nine presentations of cabozantinib data in prostate, urothelial, and other cancers - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 14, 2014-- Exelixis, Inc. (NASDAQ: EXEL) today announced that cabozantinib and cobimetinib will be the subject of ten presentations at the upcoming 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, which will be held May 30 to June 3, 2014 in Chicago, Illinois, is expected to draw more than 25,000 oncology professionals from around the world. The full roster of cabozantinib presentations expected at the meeting (all times Central Daylight Ti...

- Data from BRIM7, ongoing phase 1b trial in patients with locally advanced/unresectable or metastatic melanoma with the BRAFV600 mutation - - 87% confirmed Overall Response Rate, 13.7-month median Progression Free Survival and 83% 1 year survival estimate for the combination in BRAFi-naive patients observed in exploratory analyses of anti-tumor activity - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 7, 2014-- Exelixis, Inc. (NASDAQ:EXEL) today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group (SIX...

-- Presentations to be webcast on www.exelixis.com -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 6, 2014-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the following two investor conferences in May: Bank of America Merrill Lynch 2014 Health Care Conference, Las Vegas: The Exelixis presentation is scheduled for 11:40 a.m. EDT / 8:40 a.m. PDT on Tuesday, May 13. UBS 2014 Global Healthcare Conference, New York: The Exelixis presentation i...

- Conference Call and Webcast Today at 5:00 PM Eastern Time - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 1, 2014-- Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended March 31, 2014. Q1 2014 Highlights and Recent Events The European Commission approved COMETRIQ® (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid cancer in January 2014. Additionally, the Committee for Orphan Medicinal Products recommended maintenance of orphan drug designation at the time of marketing...

- Conference Call and Webcast to Follow - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 21, 2014-- Exelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2014 financial results on Thursday, May 1, 2014 after the markets close. The announcement will be followed by a live conference call and webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT. During the presentation, Exelixis management will discuss the Company's financial results and provide a general business update. The conference call will be webcast live and may be accessed in the Event Calendar page under Investors & Media at www.exelixis.com. Please c...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 25, 2014-- Exelixis, Inc. (NASDAQ:EXEL) announced that the Independent Data Monitoring Committee (IDMC) notified the company today that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis continues to anticipate top-line data from COMET-1 in 2014. About the COMET-1 Trial COMET-1 is a randomized, double-blind, controlled trial designed to enroll 960 patients with mCRPC who have progressed after treatment with docetaxel, abiraterone and/or enzalutam...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 25, 2014-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Commission has approved COMETRIQ® (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). The European Commission granted conditional marketing authorization following a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) issued in December 2013. Similar to another drug approved in this setting, the approved indication states that for patients in whom Rearranged during Transfectio...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 26, 2014-- Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at the 34th Annual Cowen and Company Health Care Conference at 10:00 a.m. EST/7:00 a.m. PST on Tuesday, March 4, 2014 in Boston. During the presentation, Dr. Morrissey will review the company’s development plans and priorities for cabozantinib in 2014. He will also discuss the company’s corporate strategy and financial outlook, and provide a general business update. The presentation will be webcast and m...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 20, 2014-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2013. Q4 2013 Highlights and Recent Events Completed enrollment in COMET-1, the phase 3 study of cabozantinib versus prednisone with the primary endpoint of overall survival in patients with advanced metastatic castration-resistant prostate cancer (CRPC). The study reached its enrollment target of 960 patients in September 2013 and the enrollment was closed in November 2013. Received a positive opinion fro...